Cancer Research Technology Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile
- GDPH103762D
- Pages: 70
- September 2018
- Total Views:1317
- Region : Europe
- GlobalData
- Equity Research Report
Details
Summary
Cancer Research Technology Ltd (CRT), formerly Cancer Research Campaign Technology Ltd, a subsidiary of Cancer Research UK, is a research organization that develops and commercializes discoveries for treatment in the areas of cancer. The organization offers services such as project development, drug discovery, commercialization, clinical development, imaging, and funding. It provides commercialization services to oncology institutes and also operates drug discovery laboratories. CRT serves pharmaceutical companies, clinical and academic institutions, and biotechnology companies. It provides online reagents research portal for the life science community. The organization operates in Massachusetts, the US and Cambridge, the UK. CRT is headquartered in London, the UK.
Cancer Research Technology Ltd-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table Of Content
Scope
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 6
Cancer Research Technology Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Cancer Research Technology Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Cancer Research Technology Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Cancer Research Technology Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Cancer Research Technology Ltd, Medical Devices Deals, 2012 to YTD 2018 11
Cancer Research Technology Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Cancer Research Technology Ltd, Pharmaceuticals & Healthcare, Deal Details 16
Venture Financing 16
GammaDelta Therapeutics Raises Funds through Seed Financing 16
ADC Therapeutics To Raise USD 50 Million In Venture Financing 17
Partnerships 19
Cancer Research Technology Enters into Partnership with Celgene 19
Cancer Research Technology Enters into Agreement with Merck 20
Tusk Therapeutics Enters into Agreement with University College London and Cancer Research Technology 21
MRC Technology, Cancer Research UK and Cancer Research Technology Enter into Partnership 22
Cancer Research UK, Cancer Research Technology to Enter into Agreement with TYG Oncology 23
Artios Pharma Research Agreement with Cancer Research Technology 24
CiMaas Enters into Agreement with Cancer Research Technology and University of Copenhagen 25
Cell Therapy Catapult Enters into Joint venture Agreement with University of Birmingham and Cancer Research Technology 26
Monopar Therapeutics Enters into Agreement with Cancer Research UK and Cancer Research Technology 27
Medivir Enters into Development Agreement with Cancer Research Technology 28
BioInvent And CRT Enter Into Research Agreement With University Of Southampton 29
Cancer Research and Cancer Research Technology Enter into Co-Development Agreement with Astellas Pharma 30
Nuevolution Enters Into Agreement With Cancer Research Technology And Institute Of Cancer Research For Drug Discovery 31
Cancer Research UK Enters Into Co-Development Agreement With AstraZeneca 33
GlaxoSmithKline Enters Into Agreement With Cancer Research Technology And University of Manchester For Cancer Drugs 34
HitGen Enters into Drug Discovery Agreement with Cancer Research UK and Cancer Research Technology 35
Cancer Research Technology Enters Into Agreement With Nuevolution For Anti-Cancer Drug Molecule Discovery 36
Cancer Research Technology And Teva Enter Into R&D Agreement To Develop Cancer Drugs 37
Cancer Research Technology And Institute of Cancer Research Enter Into Agreement With Merck Serono For Drug Discovery 38
Forma Therapeutics Expands Discovery Agreement with Cancer Research Technology 39
Cancer Research Technology, University of Manchester And AstraZeneca Enters Into Agreement To Develop Cancer Drugs 40
Janssen Biotech Enters Into Agreement With CRT And ICR To Discover Multiple Myeloma Drug 41
Astex Pharma, Cancer Research Technology And Institute of Cancer Research Enter Into Epigenetic Drug Discovery Agreement 42
Cancer Research Technology Enters Into Co-Development Agreement With ADC Therapeutics For Antibody Drug Conjugates 44
BioInvent And Cancer Research Technology Enter Into Co-Development Agreement With Queen Mary, University of London 46
Licensing Agreements 47
Cancer Research UK and Cancer Research Technology Enter into Licensing Agreement with HitGen 47
Tusk Therapeutics Enters into Licensing Agreement with University College London and Cancer Research Technology 48
Amplia Therapeutics Enters into Licensing Agreement with Cancer Research Technology 49
Cancer Research Technology Enters into Licensing Agreement with Pangaea Biotech 50
Merck Enters into Licensing Agreement with Cancer Research Technology 51
Nemucore Medical Innovations Enters into Licensing Agreement with Cancer Research Technology 52
Basilea Pharma Enters into Licensing Agreement for Novel PanRAF Kinase Inhibitors 53
Immatics Biotech, Cancer Research UK and Cancer Research Technology Enter into Licensing Agreement 54
Alchemia Enters Into Licensing Agreement With Cancer Research Technology For FAK Inhibitors 55
Cancer Research Technology Enters into Licensing Agreement with Cancer Therapeutics CRC 56
Artios Pharma Enters into Licensing Agreement with Cancer Research Technology 57
BioInvent Enters into Licensing Agreement with University of Southampton and Cancer Research Technology 58
Epistem Holdings and CRT Enter into Licensing Agreement with Newcastle University 59
Cancer Research Technology, Cardiff University, And Institute of Cancer Research Extend Licensing Agreement With Merck Serono 60
Equity Offering 62
iOnctura Spin Out from Merck and Cancer Research Technology 62
Cancer Research Technology Ltd-Key Competitors 63
Cancer Research Technology Ltd-Key Employees 64
Cancer Research Technology Ltd-Locations And Subsidiaries 65
Head Office 65
Other Locations & Subsidiaries 65
Joint Venture 65
Recent Developments 67
Government and Public Interest 67
Jun 13, 2018: Cryo-EM reveals interaction between major drug targets 67
Apr 19, 2017: CRT pioneer fund, Cancer Research UK and NCI collaborate to boost research against the 'undruggable' RAS 69
Appendix 70
Methodology 70
About GlobalData 70
Contact Us 70
Disclaimer 70
List Of Figure
List of Figures
Cancer Research Technology Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Cancer Research Technology Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Cancer Research Technology Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Cancer Research Technology Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Cancer Research Technology Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Cancer Research Technology Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8
Cancer Research Technology Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Cancer Research Technology Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Cancer Research Technology Ltd, Medical Devices Deals, 2012 to YTD 2018 11
List Of Table
List of Tables
Cancer Research Technology Ltd, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Cancer Research Technology Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Cancer Research Technology Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Cancer Research Technology Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Cancer Research Technology Ltd, Deals By Therapy Area, 2012 to YTD 2018 10
Cancer Research Technology Ltd, Medical Devices Deals, 2012 to YTD 2018 11
Cancer Research Technology Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
GammaDelta Therapeutics Raises Funds through Seed Financing 16
ADC Therapeutics To Raise USD 50 Million In Venture Financing 17
Cancer Research Technology Enters into Partnership with Celgene 19
Cancer Research Technology Enters into Agreement with Merck 20
Tusk Therapeutics Enters into Agreement with University College London and Cancer Research Technology 21
MRC Technology, Cancer Research UK and Cancer Research Technology Enter into Partnership 22
Cancer Research UK, Cancer Research Technology to Enter into Agreement with TYG Oncology 23
Artios Pharma Research Agreement with Cancer Research Technology 24
CiMaas Enters into Agreement with Cancer Research Technology and University of Copenhagen 25
Cell Therapy Catapult Enters into Joint venture Agreement with University of Birmingham and Cancer Research Technology 26
Monopar Therapeutics Enters into Agreement with Cancer Research UK and Cancer Research Technology 27
Medivir Enters into Development Agreement with Cancer Research Technology 28
BioInvent And CRT Enter Into Research Agreement With University Of Southampton 29
Cancer Research and Cancer Research Technology Enter into Co-Development Agreement with Astellas Pharma 30
Nuevolution Enters Into Agreement With Cancer Research Technology And Institute Of Cancer Research For Drug Discovery 31
Cancer Research UK Enters Into Co-Development Agreement With AstraZeneca 33
GlaxoSmithKline Enters Into Agreement With Cancer Research Technology And University of Manchester For Cancer Drugs 34
HitGen Enters into Drug Discovery Agreement with Cancer Research UK and Cancer Research Technology 35
Cancer Research Technology Enters Into Agreement With Nuevolution For Anti-Cancer Drug Molecule Discovery 36
Cancer Research Technology And Teva Enter Into R&D Agreement To Develop Cancer Drugs 37
Cancer Research Technology And Institute of Cancer Research Enter Into Agreement With Merck Serono For Drug Discovery 38
Forma Therapeutics Expands Discovery Agreement with Cancer Research Technology 39
Cancer Research Technology, University of Manchester And AstraZeneca Enters Into Agreement To Develop Cancer Drugs 40
Janssen Biotech Enters Into Agreement With CRT And ICR To Discover Multiple Myeloma Drug 41
Astex Pharma, Cancer Research Technology And Institute of Cancer Research Enter Into Epigenetic Drug Discovery Agreement 42
Cancer Research Technology Enters Into Co-Development Agreement With ADC Therapeutics For Antibody Drug Conjugates 44
BioInvent And Cancer Research Technology Enter Into Co-Development Agreement With Queen Mary, University of London 46
Cancer Research UK and Cancer Research Technology Enter into Licensing Agreement with HitGen 47
Tusk Therapeutics Enters into Licensing Agreement with University College London and Cancer Research Technology 48
Amplia Therapeutics Enters into Licensing Agreement with Cancer Research Technology 49
Cancer Research Technology Enters into Licensing Agreement with Pangaea Biotech 50
Merck Enters into Licensing Agreement with Cancer Research Technology 51
Nemucore Medical Innovations Enters into Licensing Agreement with Cancer Research Technology 52
Basilea Pharma Enters into Licensing Agreement for Novel PanRAF Kinase Inhibitors 53
Immatics Biotech, Cancer Research UK and Cancer Research Technology Enter into Licensing Agreement 54
Alchemia Enters Into Licensing Agreement With Cancer Research Technology For FAK Inhibitors 55
Cancer Research Technology Enters into Licensing Agreement with Cancer Therapeutics CRC 56
Artios Pharma Enters into Licensing Agreement with Cancer Research Technology 57
BioInvent Enters into Licensing Agreement with University of Southampton and Cancer Research Technology 58
Epistem Holdings and CRT Enter into Licensing Agreement with Newcastle University 59
Cancer Research Technology, Cardiff University, And Institute of Cancer Research Extend Licensing Agreement With Merck Serono 60
iOnctura Spin Out from Merck and Cancer Research Technology 62
Cancer Research Technology Ltd, Key Competitors 63
Cancer Research Technology Ltd, Key Employees 64
Cancer Research Technology Ltd, Other Locations 65
Cancer Research Technology Ltd, Subsidiaries 65
Cancer Research Technology Ltd, Joint Venture 65
Licence Rights
Single User License:
Report can be used by individual purchaser only
Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office
Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company
Section Purchase
INQUIRE FOR COVID-19 IMPACT ANALYSIS
Products and Companies
Products
Cancer Research Technology Ltd, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Company Profile
Company Profile Title
Summary
Cancer Research Technology Ltd (CRT), formerly Cancer Research Campaign Technology Ltd, a subsidiary of Cancer Research UK, is a research organization that develops and commercializes discoveries for treatment in the areas of cancer. The organization offers services such as project development, drug discovery, commercialization, clinical development, imaging, and funding. It provides commercialization services to oncology institutes and also operates drug discovery laboratories. CRT serves pharmaceutical companies, clinical and academic institutions, and biotechnology companies. It provides online reagents research portal for the life science community. The organization operates in Massachusetts, the US and Cambridge, the UK. CRT is headquartered in London, the UK.
Cancer Research Technology Ltd-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Scope
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 6
Cancer Research Technology Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Cancer Research Technology Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Cancer Research Technology Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Cancer Research Technology Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Cancer Research Technology Ltd, Medical Devices Deals, 2012 to YTD 2018 11
Cancer Research Technology Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Cancer Research Technology Ltd, Pharmaceuticals & Healthcare, Deal Details 16
Venture Financing 16
GammaDelta Therapeutics Raises Funds through Seed Financing 16
ADC Therapeutics To Raise USD 50 Million In Venture Financing 17
Partnerships 19
Cancer Research Technology Enters into Partnership with Celgene 19
Cancer Research Technology Enters into Agreement with Merck 20
Tusk Therapeutics Enters into Agreement with University College London and Cancer Research Technology 21
MRC Technology, Cancer Research UK and Cancer Research Technology Enter into Partnership 22
Cancer Research UK, Cancer Research Technology to Enter into Agreement with TYG Oncology 23
Artios Pharma Research Agreement with Cancer Research Technology 24
CiMaas Enters into Agreement with Cancer Research Technology and University of Copenhagen 25
Cell Therapy Catapult Enters into Joint venture Agreement with University of Birmingham and Cancer Research Technology 26
Monopar Therapeutics Enters into Agreement with Cancer Research UK and Cancer Research Technology 27
Medivir Enters into Development Agreement with Cancer Research Technology 28
BioInvent And CRT Enter Into Research Agreement With University Of Southampton 29
Cancer Research and Cancer Research Technology Enter into Co-Development Agreement with Astellas Pharma 30
Nuevolution Enters Into Agreement With Cancer Research Technology And Institute Of Cancer Research For Drug Discovery 31
Cancer Research UK Enters Into Co-Development Agreement With AstraZeneca 33
GlaxoSmithKline Enters Into Agreement With Cancer Research Technology And University of Manchester For Cancer Drugs 34
HitGen Enters into Drug Discovery Agreement with Cancer Research UK and Cancer Research Technology 35
Cancer Research Technology Enters Into Agreement With Nuevolution For Anti-Cancer Drug Molecule Discovery 36
Cancer Research Technology And Teva Enter Into R&D Agreement To Develop Cancer Drugs 37
Cancer Research Technology And Institute of Cancer Research Enter Into Agreement With Merck Serono For Drug Discovery 38
Forma Therapeutics Expands Discovery Agreement with Cancer Research Technology 39
Cancer Research Technology, University of Manchester And AstraZeneca Enters Into Agreement To Develop Cancer Drugs 40
Janssen Biotech Enters Into Agreement With CRT And ICR To Discover Multiple Myeloma Drug 41
Astex Pharma, Cancer Research Technology And Institute of Cancer Research Enter Into Epigenetic Drug Discovery Agreement 42
Cancer Research Technology Enters Into Co-Development Agreement With ADC Therapeutics For Antibody Drug Conjugates 44
BioInvent And Cancer Research Technology Enter Into Co-Development Agreement With Queen Mary, University of London 46
Licensing Agreements 47
Cancer Research UK and Cancer Research Technology Enter into Licensing Agreement with HitGen 47
Tusk Therapeutics Enters into Licensing Agreement with University College London and Cancer Research Technology 48
Amplia Therapeutics Enters into Licensing Agreement with Cancer Research Technology 49
Cancer Research Technology Enters into Licensing Agreement with Pangaea Biotech 50
Merck Enters into Licensing Agreement with Cancer Research Technology 51
Nemucore Medical Innovations Enters into Licensing Agreement with Cancer Research Technology 52
Basilea Pharma Enters into Licensing Agreement for Novel PanRAF Kinase Inhibitors 53
Immatics Biotech, Cancer Research UK and Cancer Research Technology Enter into Licensing Agreement 54
Alchemia Enters Into Licensing Agreement With Cancer Research Technology For FAK Inhibitors 55
Cancer Research Technology Enters into Licensing Agreement with Cancer Therapeutics CRC 56
Artios Pharma Enters into Licensing Agreement with Cancer Research Technology 57
BioInvent Enters into Licensing Agreement with University of Southampton and Cancer Research Technology 58
Epistem Holdings and CRT Enter into Licensing Agreement with Newcastle University 59
Cancer Research Technology, Cardiff University, And Institute of Cancer Research Extend Licensing Agreement With Merck Serono 60
Equity Offering 62
iOnctura Spin Out from Merck and Cancer Research Technology 62
Cancer Research Technology Ltd-Key Competitors 63
Cancer Research Technology Ltd-Key Employees 64
Cancer Research Technology Ltd-Locations And Subsidiaries 65
Head Office 65
Other Locations & Subsidiaries 65
Joint Venture 65
Recent Developments 67
Government and Public Interest 67
Jun 13, 2018: Cryo-EM reveals interaction between major drug targets 67
Apr 19, 2017: CRT pioneer fund, Cancer Research UK and NCI collaborate to boost research against the 'undruggable' RAS 69
Appendix 70
Methodology 70
About GlobalData 70
Contact Us 70
Disclaimer 70
List Of Figure
List of Figures
Cancer Research Technology Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Cancer Research Technology Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Cancer Research Technology Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Cancer Research Technology Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Cancer Research Technology Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Cancer Research Technology Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8
Cancer Research Technology Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Cancer Research Technology Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Cancer Research Technology Ltd, Medical Devices Deals, 2012 to YTD 2018 11
List Of Table
List of Tables
Cancer Research Technology Ltd, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Cancer Research Technology Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Cancer Research Technology Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Cancer Research Technology Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Cancer Research Technology Ltd, Deals By Therapy Area, 2012 to YTD 2018 10
Cancer Research Technology Ltd, Medical Devices Deals, 2012 to YTD 2018 11
Cancer Research Technology Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
GammaDelta Therapeutics Raises Funds through Seed Financing 16
ADC Therapeutics To Raise USD 50 Million In Venture Financing 17
Cancer Research Technology Enters into Partnership with Celgene 19
Cancer Research Technology Enters into Agreement with Merck 20
Tusk Therapeutics Enters into Agreement with University College London and Cancer Research Technology 21
MRC Technology, Cancer Research UK and Cancer Research Technology Enter into Partnership 22
Cancer Research UK, Cancer Research Technology to Enter into Agreement with TYG Oncology 23
Artios Pharma Research Agreement with Cancer Research Technology 24
CiMaas Enters into Agreement with Cancer Research Technology and University of Copenhagen 25
Cell Therapy Catapult Enters into Joint venture Agreement with University of Birmingham and Cancer Research Technology 26
Monopar Therapeutics Enters into Agreement with Cancer Research UK and Cancer Research Technology 27
Medivir Enters into Development Agreement with Cancer Research Technology 28
BioInvent And CRT Enter Into Research Agreement With University Of Southampton 29
Cancer Research and Cancer Research Technology Enter into Co-Development Agreement with Astellas Pharma 30
Nuevolution Enters Into Agreement With Cancer Research Technology And Institute Of Cancer Research For Drug Discovery 31
Cancer Research UK Enters Into Co-Development Agreement With AstraZeneca 33
GlaxoSmithKline Enters Into Agreement With Cancer Research Technology And University of Manchester For Cancer Drugs 34
HitGen Enters into Drug Discovery Agreement with Cancer Research UK and Cancer Research Technology 35
Cancer Research Technology Enters Into Agreement With Nuevolution For Anti-Cancer Drug Molecule Discovery 36
Cancer Research Technology And Teva Enter Into R&D Agreement To Develop Cancer Drugs 37
Cancer Research Technology And Institute of Cancer Research Enter Into Agreement With Merck Serono For Drug Discovery 38
Forma Therapeutics Expands Discovery Agreement with Cancer Research Technology 39
Cancer Research Technology, University of Manchester And AstraZeneca Enters Into Agreement To Develop Cancer Drugs 40
Janssen Biotech Enters Into Agreement With CRT And ICR To Discover Multiple Myeloma Drug 41
Astex Pharma, Cancer Research Technology And Institute of Cancer Research Enter Into Epigenetic Drug Discovery Agreement 42
Cancer Research Technology Enters Into Co-Development Agreement With ADC Therapeutics For Antibody Drug Conjugates 44
BioInvent And Cancer Research Technology Enter Into Co-Development Agreement With Queen Mary, University of London 46
Cancer Research UK and Cancer Research Technology Enter into Licensing Agreement with HitGen 47
Tusk Therapeutics Enters into Licensing Agreement with University College London and Cancer Research Technology 48
Amplia Therapeutics Enters into Licensing Agreement with Cancer Research Technology 49
Cancer Research Technology Enters into Licensing Agreement with Pangaea Biotech 50
Merck Enters into Licensing Agreement with Cancer Research Technology 51
Nemucore Medical Innovations Enters into Licensing Agreement with Cancer Research Technology 52
Basilea Pharma Enters into Licensing Agreement for Novel PanRAF Kinase Inhibitors 53
Immatics Biotech, Cancer Research UK and Cancer Research Technology Enter into Licensing Agreement 54
Alchemia Enters Into Licensing Agreement With Cancer Research Technology For FAK Inhibitors 55
Cancer Research Technology Enters into Licensing Agreement with Cancer Therapeutics CRC 56
Artios Pharma Enters into Licensing Agreement with Cancer Research Technology 57
BioInvent Enters into Licensing Agreement with University of Southampton and Cancer Research Technology 58
Epistem Holdings and CRT Enter into Licensing Agreement with Newcastle University 59
Cancer Research Technology, Cardiff University, And Institute of Cancer Research Extend Licensing Agreement With Merck Serono 60
iOnctura Spin Out from Merck and Cancer Research Technology 62
Cancer Research Technology Ltd, Key Competitors 63
Cancer Research Technology Ltd, Key Employees 64
Cancer Research Technology Ltd, Other Locations 65
Cancer Research Technology Ltd, Subsidiaries 65
Cancer Research Technology Ltd, Joint Venture 65
Single User License:
Report can be used by individual purchaser only
Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office
Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company
INQUIRE FOR COVID-19 IMPACT ANALYSIS
Products
Cancer Research Technology Ltd, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
: +91 9015378249
Related Reports
Page 69 | 
May 2022
Page 76 | April 2022
Page 68 | March 2022
Page 78 | March 2022
Page 56 | October 2021